Free Trial

Verrica Pharmaceuticals (VRCA) Competitors

Verrica Pharmaceuticals logo
$6.61 -0.39 (-5.57%)
Closing price 04:00 PM Eastern
Extended Trading
$6.78 +0.18 (+2.65%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRCA vs. ALDX, VOR, CRVS, SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, and ZYBT

Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

Verrica Pharmaceuticals vs. Its Competitors

Verrica Pharmaceuticals (NASDAQ:VRCA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Verrica Pharmaceuticals and 1 mentions for Aldeyra Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Aldeyra Therapeutics' score of 1.26 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Verrica Pharmaceuticals Very Positive
Aldeyra Therapeutics Positive

Verrica Pharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Verrica Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 21.03%. Aldeyra Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 83.75%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Verrica Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verrica Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Aldeyra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Verrica Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Verrica PharmaceuticalsN/A N/A -145.63%
Aldeyra Therapeutics N/A -72.58%-52.32%

Aldeyra Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verrica Pharmaceuticals$7.57M80.76-$76.58M-$1.20-5.51
Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-5.33

Summary

Aldeyra Therapeutics beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRCA vs. The Competition

MetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$64.74M$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-5.519.0528.0720.06
Price / Sales80.76757.79449.2099.44
Price / CashN/A165.2136.2258.56
Price / Book-60.095.168.665.87
Net Income-$76.58M$30.99M$3.25B$258.55M
7 Day Performance709.75%7.74%4.20%2.23%
1 Month Performance1,001.67%16.18%10.82%12.76%
1 Year Performance-8.83%-1.03%34.70%19.36%

Verrica Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCA
Verrica Pharmaceuticals
4.1333 of 5 stars
$6.61
-5.6%
$8.00
+21.0%
-90.2%$64.74M$7.57M-5.5140Positive News
Gap Down
ALDX
Aldeyra Therapeutics
2.7521 of 5 stars
$5.01
+7.7%
$9.50
+89.6%
+39.1%$300.08MN/A-5.1610Positive News
Upcoming Earnings
VOR
Vor Biopharma
3.8804 of 5 stars
$2.39
-4.4%
$5.63
+135.5%
+129.7%$298.65MN/A-1.45140High Trading Volume
CRVS
Corvus Pharmaceuticals
2.6722 of 5 stars
$4.35
+5.1%
$15.00
+244.8%
+118.9%$296.54MN/A-4.4430Positive News
SGMT
Sagimet Biosciences
2.6714 of 5 stars
$9.46
-0.1%
$26.60
+181.2%
+222.8%$290.14M$2M-5.388News Coverage
Analyst Forecast
Insider Trade
DBVT
DBV Technologies
3.9009 of 5 stars
$10.58
-2.1%
$14.75
+39.5%
+102.4%$289.68M$4.15M-2.1580Upcoming Earnings
Gap Up
ANNX
Annexon
2.4431 of 5 stars
$2.61
+1.2%
$12.50
+378.9%
-58.1%$286.34MN/A-2.2160
AVTE
Aerovate Therapeutics
N/A$9.82
-6.7%
N/A-86.8%$284.63MN/A-3.2820High Trading Volume
ALLO
Allogene Therapeutics
3.2575 of 5 stars
$1.29
+0.8%
$8.44
+554.6%
-48.1%$282.16M$20K-1.05310Positive News
TVRD
Tvardi Therapeutics
N/A$29.83
+9.1%
$64.25
+115.4%
N/A$279.21M$7.14M0.0080Gap Up
High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$5.87
-0.3%
N/AN/A$276.86M$186.36M0.00278Positive News

Related Companies and Tools


This page (NASDAQ:VRCA) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners